MedPath

Effects of a Phone Call Intervention to Promote HAART Adherence

Not Applicable
Conditions
Medication Adherence
Interventions
Behavioral: Phone call intervention, no phone call intervention
Registration Number
NCT01395771
Lead Sponsor
Baoshan Prefecture Center for Disease Control and Prevention
Brief Summary

The adherence rate (95%) to HAART in the intervention group which receives a phone call will be higher than that(75%)of control group which does not receive a phone call.

Detailed Description

According to above eligibility criteria, getting two eligible group patients, one which are patients newly required HAART (new cases) and the other who have received HAART for 1-3 years(old cases). All eligible patients in each group will be randomly assigned to intervention and control group by block randomization. Among of them, one group with a phone call intervention, the other without. New cases will be followed up for 3 months and study outcomes will be assessed at the baseline and the 2nd week, the 1st month and 2nd month, and the 3rd month. For the old cases, study outcomes will be assessed only at the baseline survey and at the 3rd month.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Phone callPhone call intervention, no phone call interventionNew cases and old cases will be randomly categorized into two groups,respectively,one is phone call intervention group, the other is no phone call intervention group.
Primary Outcome Measures
NameTimeMethod
Change from baseline HAART adherence within 3 monthsHAART adherence for new cases will be assessed at the 2nd week, the 1st month and 2nd month, and the 3rd month follow-up. For old cases HAART adherence will be assessed only at the baseline survey and the 3rd month follow-up

Adherence will be measured at different time points within 3 months follow-up (study period)

Secondary Outcome Measures
NameTimeMethod
CD4 cell countsCD4 will be measured at the baseline survey and the 3rd month follow-up

CD4 cell counts will be measured only at baseline survey and after 3 months

Change from baseline quality of life within 3 monthsQuality of life for new cases will be assessed at the baseline survey and the 2nd week, the 1st month and 2nd month, and the 3rd month. For old cases quality of life will be assessed only at the baseline survey and the end of the 3rd month

Quality of life will be measured at different time points within 3 months study periods

Number of patients with side effectsNumber of side effects for new cases will be assessed at the 2nd week, the 1st month and 2nd month, and the 3rd month follow-up. For old cases the number of side effects will be assessed only at the baseline survey and the 3rd month follow-up

The number of side effects will be measured at different time points within 3 months follow-up period

Number of opportunistic infection within 3 monthsNumber of opportunistic infection for new cases will be assessed at the 2nd week, the 1st month and 2nd month, and the 3rd month follow-up. For old cases number of that will be assessed only at the baseline and the 3rd month follow-up

Number of opportunistic infection will be measured at different time points within 3 months follow-up period(study period)

MortalityMortality will be assessed the 3rd month follow-up

Measurement of the number of change of mortality

Trial Locations

Locations (4)

Longling county hospital

🇨🇳

Baoshan, Yunnan, China

Longyang district hospital

🇨🇳

Baoshan, Yunnan, China

The first hospital of Baoshan Prefecture

🇨🇳

Baoshan, Yunnan, China

Tengchong county hospital

🇨🇳

Baoshan, Yunnan, China

© Copyright 2025. All Rights Reserved by MedPath